Mavenclad (Cladribine Tablets) Receives First Approval in Latin America
- First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina. - Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years.
- 27.02.2018, 09:42
- Kategoria: Biznes i finanse
- Źródło: PR Newswire